Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape

Xie, Danni; Jin, Xin; Sun, Rui; Zhang, Meng; Lu, Wenyi; Cao, Xinping; Guo, Ruiting; Zhang, Yi; Zhao, Mingfeng

doi:10.1016/j.tranon.2023.101695

Cited by 8 publications

(1 citation statement)

References 26 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 50 Xie et al . 51 recently designed a CD123 and CLL1 dual-targeted CAR-T therapy (123CL-CAR-T) and reported that it exhibited robust in vivo and in vitro antitumor activity against AML cells expressing either of the two targets. Dual-target CAR-T cells are also the subject of a clinical trial (NCT03795779).…”

Section: Reasons For Car-t Treatment Failure and Strategies For Overc...mentioning

confidence: 99%

Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia

Zha,

Song,

Wan

et al. 2024

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Chimeric antigen receptor T-cell (CAR-T) therapy, which has demonstrated notable efficacy against B-cell malignancies and is approved by the US Food and Drug Administration for clinical use in this context, represents a significant milestone in cancer immunotherapy. However, the efficacy of CAR-T therapy for the treatment of acute myeloid leukemia (AML) is poor. The challenges associated with the application of CAR-T therapy for the clinical treatment of AML include, but are not limited to, nonspecific distribution of AML therapeutic targets, difficulties in the production of CAR-T cells, AML blast cell heterogeneity, the immunosuppressive microenvironment in AML, and treatment-related adverse events. In this review, we summarize the recent findings regarding various therapeutic targets for AML (CD33, CD123, CLL1, CD7, etc.) and the results of the latest clinical studies on these targets. Thereafter, we also discuss the challenges related to CAR-T therapy for AML and some promising strategies for overcoming these challenges, including novel approaches such as gene editing and advances in CAR design.

show abstract

Section: Reasons For Car-t Treatment Failure and Strategies For Overc...mentioning

confidence: 99%

Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia

Zha,

Song,

Wan

et al. 2024

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

show abstract

Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies

Kandav,

Chandel

2024

Med Oncol

View full text Add to dashboard Cite

Bringing cell therapy to tumors: considerations for optimal CAR binder design

Smith

2023

Antibody Therapeutics

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR)-T cells have revolutionized the immunotherapy of B-cell malignancies and are poised to expand the range of their impact across a broad range of oncology and non-oncology indications. Critical to the success of a given CAR is the choice of binding domain, as this is the key driver for specificity and plays an important role (along with the rest of the CAR structure) in determining efficacy, potency and durability of the cell therapy. While antibodies have proven to be effective sources of CAR binding domains, it has become apparent that the desired attributes for a CAR binding domain do differ from those of a recombinant antibody. This review will address key factors that need to be considered in choosing the optimal binding domain for a given CAR and how binder properties influence and are influenced by the rest of the CAR.

show abstract

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape

Cited by 8 publications

References 26 publications

Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia

Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia

Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies

Bringing cell therapy to tumors: considerations for optimal CAR binder design

Contact Info

Product

Resources

About